BioLineRx Ltd.
BLRX
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarciā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.02
Price+4.42%
$0.17
1Y
Price
Market Cap
$321.023m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$17.251m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$7.822m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$1.05
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$20.072m
$43.267m
Assets$23.195m
Liabilities$12.603m
DebtDebt to Assets
29.1%
6.4x
Debt to EBITDAFree Cash Flow
-$21.198m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company